European Companies Search Engine
EU funding (€14.5M): REspiratory Syncytial virus Consortium in EUrope - Sofia ref.: 116019 Hor1 Jan 2017 EU Research and Innovation programme "Horizon"
Overview
Text
REspiratory Syncytial virus Consortium in EUrope - Sofia ref.: 116019
RSV causes severe disease and results in substantial healthcare costs in individuals at the extremes of the age spectrum and in high risk groups. RESCEU brings together academia, national public health agencies and EFPIA with proven expertise and a strong track record in RSV research. The academic partners are leaders in RSV epidemiology, clinical RSV research, health economics, and vaccinology; and key opinion leaders with advisory roles in European and national public health bodies, health technology agencies and vaccine advisory groups. EFPIA participants (AZ, GSK, JPNV, Novavax, Pfizer, and SP) have active clinical research programmes to develop lead candidates for treatment and prevention of RSV in infants, adults and the elderly. As part of RESCEU, EFPIA participants will contribute expertise in a wide range of fields including infectious disease, clinical medicine, immunology, epidemiology, biostatistics, biomarker development, global health, and health economics. RESCEU’s aim is to develop robust evidence on RSV disease burden and economic impact; create a sustainable Europe-wide multidisciplinary, multi-stakeholder community from academia, public health, scientific societies, patient organisations, regulatory agencies and industry; and provide infrastructure to perform future pivotal trials for RSV vaccines and therapeutics. RESCEU aims to provide sustainable longer term impact on RSV disease burden and thus make a significant contribution to improved health and wellbeing in Europe. The project will comprise 6 work packages. WP 1-3 will identify and marshal data from large-scale systematic reviews of epidemiological and cost studies, disease registries, linked routine (national) healthcare and claims datasets and will establish a framework for and assemble data from RSV surveillance in Europe to estimate RSV disease burden on health services and inform economic models.
Funded Companies:
| Company name | Funding amount |
| Academisch Ziekenhuis Groningen | €307,125 |
| Astrazeneca AB | €0.00 |
| €223,306 | |
| Glaxosmithkline Biologicals SA | €0.00 |
| Imperial College of Science Technology and Medicine | €860,503 |
| Janssen Pharmaceutica N.V. | €0.00 |
| Novavax Inc. | €0.00 |
| Pfizer Ltd. | €0.00 |
| €598,125 | |
| Sanofi Pasteur SA | €0.00 |
| Servizo Galego de Saude | €499,453 |
| Statens Serum Institut | €508,717 |
| Synapse Research Management Partners SL | €613,270 |
| Teamit Research SL | €480,480 |
| The Chancellor, Masters and Scholars of the University of Oxford | €2,187,350 |
| The University of Edinburgh | €3,604,783 |
| Universitair Medisch Centrum Utrecht | €2,815,388 |
| Universiteit Antwerpen | €1,203,875 |
| VARSINAIS-SUOMEN SAIRAANHOITOPIIRIN KUNTAYHTYMA | €595,750 |
Source: https://cordis.europa.eu/project/id/116019
The filing refers to a past date, and does not necessarily reflect the current state.
The visualizations for "Academisch Ziekenhuis Groningen - EU funding (€14.5M): REspiratory Syncytial virus Consortium in EUrope - Sofia ref.: 116019"
are provided by
North Data
and may be reused under the terms of the
Creative Commons CC-BY license.
